By September 30, 2025: Billing team must update PacificSource Montana Commercial formulary configuration in billing software to remove prior authorization requirements for all 60+ listed medications (Androderm, Depo-Estradiol, Estradiol patches/tablets/gels, testosterone products, Alvesco, Brztri, Apidra, Basaglar, insulin products, Alosetron, Dapagliflozin, Deflazacort, Diclofenac, Dihydroergotamine, Fluconazole, Isosorb dinitrate-hydralazine, Ivabradine, Metoclopramide, Naproxen-esomeprazole, Nilutamide, Ofloxacin, Orphenadrine, Paromomycin, Penicillamine, Phenoxybenzamine, Posaconazole, Pyrimethamine, Rufinamide, Sodium phenylbutyrate, Sumatriptan-naproxen, Tadalafil, Trientine, Voriconazole, Acyclovir cream, Brimonidine gel, Dutasteride-Tamsulosin, Fenoprofen, Fesoterodine, Fluoxetine delayed release 90mg, Frovatriptan, Gabapentin, Glutamine powder, Megestrol acetate suspension, Mirabegron, Penciclovir cream, Zolmitriptan nasal spray). Provider staff must be notified to stop requesting prior authorizations for these drugs. Verify with patients that medications are still covered under formulary or removed entirely. Update encounter forms and EHR templates to reflect coverage changes. Failure to remove prior auth requirements will result in processing delays and potential claim denials due to unnecessary authorization requests.